Cargando…

An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer

BACKGROUND: Women undergoing treatment for breast cancer require frequent clinic visits for maintenance of therapy. With COVID-19 causing health care disruptions, it is important to learn about how this population’s access to health care has changed. This study compares self-reported health care uti...

Descripción completa

Detalles Bibliográficos
Autores principales: Paladino, Andrew J., Pebley, Kinsey, Kocak, Mehmet, Krukowski, Rebecca A., Waters, Teresa M., Vidal, Gregory, Schwartzberg, Lee S., Curry, Andrea N., Graetz, Ilana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684812/
https://www.ncbi.nlm.nih.gov/pubmed/36419005
http://dx.doi.org/10.1186/s12913-022-08705-9
_version_ 1784835372188958720
author Paladino, Andrew J.
Pebley, Kinsey
Kocak, Mehmet
Krukowski, Rebecca A.
Waters, Teresa M.
Vidal, Gregory
Schwartzberg, Lee S.
Curry, Andrea N.
Graetz, Ilana
author_facet Paladino, Andrew J.
Pebley, Kinsey
Kocak, Mehmet
Krukowski, Rebecca A.
Waters, Teresa M.
Vidal, Gregory
Schwartzberg, Lee S.
Curry, Andrea N.
Graetz, Ilana
author_sort Paladino, Andrew J.
collection PubMed
description BACKGROUND: Women undergoing treatment for breast cancer require frequent clinic visits for maintenance of therapy. With COVID-19 causing health care disruptions, it is important to learn about how this population’s access to health care has changed. This study compares self-reported health care utilization and changes in factors related to health care access among women treated at a cancer center in the mid-South US before and during the pandemic. METHODS: Participants (N = 306) part of a longitudinal study to improve adjuvant endocrine therapy (AET) adherence completed pre-intervention baseline surveys about their health care utilization prior to AET initiation. Questions about the impact of COVID-19 were added after the pandemic started assessing financial loss and factors related to care. Participants were categorized into three time periods based on the survey completion date: (1) pre-COVID (December 2018 to March 2020), (2) early COVID (April 2020 – December 2020), and later COVID (January 2021 to June 2021). Negative binomial regression analyses used to compare health care utilization at different phases of the pandemic controlling for patient characteristics. RESULTS: Adjusted analyses indicated office visits declined from pre-COVID, with an adjusted average of 17.7 visits, to 12.1 visits during the early COVID period (p = 0.01) and 9.9 visits during the later COVID period (p < 0.01). Hospitalizations declined from an adjusted average 0.45 admissions during early COVID to 0.21 during later COVID, after vaccines became available (p = 0.05). Among COVID period participants, the proportion reporting changes/gaps in health insurance coverage increased from 9.5% participants during early-COVID to 14.8% in the later-COVID period (p = 0.05). The proportion reporting financial loss due to the pandemic was similar during both COVID periods (34.3% early- and 37.7% later-COVID, p = 0.72). The proportion of participants reporting delaying care or refilling prescriptions decreased from 15.2% in early-COVID to 4.9% in the later-COVID period (p = 0.04). CONCLUSION: COVID-19 caused disruptions to routine health care for women with breast cancer. Patients reported having fewer office visits at the start of the pandemic that continued to decrease even after vaccines were available. Fewer patients reported delaying in-person care as the pandemic progressed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-022-08705-9.
format Online
Article
Text
id pubmed-9684812
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96848122022-11-25 An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer Paladino, Andrew J. Pebley, Kinsey Kocak, Mehmet Krukowski, Rebecca A. Waters, Teresa M. Vidal, Gregory Schwartzberg, Lee S. Curry, Andrea N. Graetz, Ilana BMC Health Serv Res Research BACKGROUND: Women undergoing treatment for breast cancer require frequent clinic visits for maintenance of therapy. With COVID-19 causing health care disruptions, it is important to learn about how this population’s access to health care has changed. This study compares self-reported health care utilization and changes in factors related to health care access among women treated at a cancer center in the mid-South US before and during the pandemic. METHODS: Participants (N = 306) part of a longitudinal study to improve adjuvant endocrine therapy (AET) adherence completed pre-intervention baseline surveys about their health care utilization prior to AET initiation. Questions about the impact of COVID-19 were added after the pandemic started assessing financial loss and factors related to care. Participants were categorized into three time periods based on the survey completion date: (1) pre-COVID (December 2018 to March 2020), (2) early COVID (April 2020 – December 2020), and later COVID (January 2021 to June 2021). Negative binomial regression analyses used to compare health care utilization at different phases of the pandemic controlling for patient characteristics. RESULTS: Adjusted analyses indicated office visits declined from pre-COVID, with an adjusted average of 17.7 visits, to 12.1 visits during the early COVID period (p = 0.01) and 9.9 visits during the later COVID period (p < 0.01). Hospitalizations declined from an adjusted average 0.45 admissions during early COVID to 0.21 during later COVID, after vaccines became available (p = 0.05). Among COVID period participants, the proportion reporting changes/gaps in health insurance coverage increased from 9.5% participants during early-COVID to 14.8% in the later-COVID period (p = 0.05). The proportion reporting financial loss due to the pandemic was similar during both COVID periods (34.3% early- and 37.7% later-COVID, p = 0.72). The proportion of participants reporting delaying care or refilling prescriptions decreased from 15.2% in early-COVID to 4.9% in the later-COVID period (p = 0.04). CONCLUSION: COVID-19 caused disruptions to routine health care for women with breast cancer. Patients reported having fewer office visits at the start of the pandemic that continued to decrease even after vaccines were available. Fewer patients reported delaying in-person care as the pandemic progressed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-022-08705-9. BioMed Central 2022-11-23 /pmc/articles/PMC9684812/ /pubmed/36419005 http://dx.doi.org/10.1186/s12913-022-08705-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Paladino, Andrew J.
Pebley, Kinsey
Kocak, Mehmet
Krukowski, Rebecca A.
Waters, Teresa M.
Vidal, Gregory
Schwartzberg, Lee S.
Curry, Andrea N.
Graetz, Ilana
An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer
title An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer
title_full An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer
title_fullStr An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer
title_full_unstemmed An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer
title_short An examination of health care utilization during the COVID-19 pandemic among women with early-stage hormone receptor-positive breast cancer
title_sort examination of health care utilization during the covid-19 pandemic among women with early-stage hormone receptor-positive breast cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684812/
https://www.ncbi.nlm.nih.gov/pubmed/36419005
http://dx.doi.org/10.1186/s12913-022-08705-9
work_keys_str_mv AT paladinoandrewj anexaminationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT pebleykinsey anexaminationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT kocakmehmet anexaminationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT krukowskirebeccaa anexaminationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT watersteresam anexaminationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT vidalgregory anexaminationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT schwartzberglees anexaminationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT curryandrean anexaminationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT graetzilana anexaminationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT paladinoandrewj examinationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT pebleykinsey examinationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT kocakmehmet examinationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT krukowskirebeccaa examinationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT watersteresam examinationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT vidalgregory examinationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT schwartzberglees examinationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT curryandrean examinationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer
AT graetzilana examinationofhealthcareutilizationduringthecovid19pandemicamongwomenwithearlystagehormonereceptorpositivebreastcancer